The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease

Kidney International

Volumn 87, Issue 4, 2015, Pages 692-697

  Yadav, Punit ^a,b   Leung, Nelson ^c   Sanders, Paul W ^d   Cockwell, Paul ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Monoclonal gammopathy; Monoclonal gammopathy of renal significance; Multiple myeloma; Serum free light chains

Indexed keywords

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; DIAGNOSTIC ACCURACY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAIN ASSAY; KIDNEY DISEASE; KIDNEY FUNCTION; MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; PARAPROTEIN RELATED KIDNEY DISEASE; PRIORITY JOURNAL; SCREENING; SENSITIVITY ANALYSIS; BLOOD; BLOOD EXAMINATION; COMPLICATION; GLOMERULAR FILTRATION BARRIER; PARAPROTEINEMIAS; PROCEDURES; REFERENCE VALUE; RENAL INSUFFICIENCY; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE;

IMMUNOGLOBULIN LIGHT CHAIN;

GLOMERULAR FILTRATION BARRIER; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; PARAPROTEINEMIAS; REFERENCE VALUES; RENAL INSUFFICIENCY; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 84926517271     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.333     Document Type: Short Survey

References (30)

1. Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
2. Dispenzieri A, Katzmann JA, Kyle RA et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-1728.
3. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292-4295.
4. Beetham R, Wassell J, Wallage MJ et al. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 2007; 44: 516-522.
5. Hutchison CA, Harding S, Hewins P et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690.
6. Holding S, Spradbery D, Hoole R et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011; 49: 83-88.
7. Marshall T, Williams KM. Electrophoretic analysis of Bence Jones proteinuria. Electrophoresis 1999; 20: 1307-1324.
8. Graziani M, Merlini G, Petrini C et al. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003; 41: 338-346.
9. te Velthuis H, Knop I, Stam P et al. N Latex FLC-new monoclonal highperformance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011; 49: 1323-1332.
10. Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013; 51: 2303-2310.
11. Campbell JP, Cobbold M, Wang Y et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013; 391: 1-13.
12. Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
13. Nowrousian MR, Brandhorst D, Sammet C et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-8714.
14. Katzmann JA, Dispenzieri A, Kyle RA et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-1578.
15. Piehler AP, Gulbrandsen N, Kierulf P et al. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008; 54: 1823-1830.
16. Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem 2009; 46: 407-412.
17. Katzmann JA, Abraham RS, Dispenzieri A et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878-881.
18. Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
19. Hutchison CA, Cockwell P, Harding S et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin Ther Targets 2008; 12: 667-676.
20. Hutchison CA, Plant T, Drayson M et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008; 9: 11.
21. Tate J, Bazeley S, Sykes S et al. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009; 30: 131-140.
22. Wang L, Chan PC. Measurement uncertainty for serum free light chain assays: estimation and implication on result interpretation. Clin Biochem 2013; 46: 381-384.
23. Pretorius CJ, Klingberg S, Tate J et al. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012; 49: 450-455.
24. Novak L, Cook WJ, Herrera GA et al. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant 2004; 19: 3050-3053.
25. Singhal S, Stein R, Vickrey E et al. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611-3612.
26. Palladini G, Russo P, Bosoni T et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504.
27. Levinson SS. Urine immunofixation electrophoresis remains important and is complementary to serum free light chain. Clin Chem Lab Med 2011; 49: 1801-1804.
28. Hill PG, Forsyth JM, Rai B et al. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743-1748.
29. Rao M, Yu WW, Chan J et al. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias. Agency for Healthcare Research and Quality: Rockville, MD, USA, 2012.
30. Rao M, Lamont JL, Chan J et al. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 73. Agency for Healthcare Research and Quality: Rockville, MD, USA, 2012.